October 19, 2004Current Opinion in Cardiology
Biomarkers in pulmonary embolism
Key result
Elevated cardiac biomarkers in pulmonary embolism showed positive predictive values for in-hospital mortality of 6 to 44% and negative predictive values for uneventful outcome above 93%.
Why the study?
Can cardiac biomarkers identify normotensive pulmonary embolism patients at high risk for adverse outcomes to justify thrombolytic therapy?
Population
Normotensive patients with pulmonary embolism
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Insufficient PPV limits biomarker-guided thrombolysis in normotensive PE; leaves open prospective validation of integrated risk models.
Structured PICO
Can cardiac biomarkers identify normotensive pulmonary embolism patients at high risk for adverse outcomes to justify thrombolytic therapy?
P
Population
Normotensive patients with pulmonary embolism
E
Exposure
Risk assessment using cardiac biomarkers (Troponin I, Troponin T, and brain natriuretic peptide [BNP])
O
Outcome
In-hospital mortality or early recurrent venous thromboembolismhard clinical
While elevated cardiac biomarkers correlate with in-hospital mortality in pulmonary embolism, their positive predictive value is insufficient to broadly recommend thrombolytic therapy based on biomarkers alone.
Cite This Study
Söhne et al. (2004) conducted a review in pulmonary embolism. Elevated cardiac biomarkers (Troponin I, T, BNP) was evaluated on in-hospital mortality. Elevated cardiac biomarkers in pulmonary embolism showed positive predictive values for in-hospital mortality of 6 to 44% and negative predictive values for uneventful outcome above 93%.